These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 8854016)

  • 1. Regulatory considerations for new stabilised poliovaccines.
    Milstien JB; Lemon S
    Dev Biol Stand; 1996; 87():181-9. PubMed ID: 8854016
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The replacement of water with deuterium oxide significantly improves the thermal stability of the oral poliovirus vaccine.
    Crainic R; Wu R; Otelea D; Georgescu MM; Delpeyroux F; Guillot S; Balanant J; Tardy-Panit M
    Dev Biol Stand; 1996; 87():161-6. PubMed ID: 8854013
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thermostability of poliovirus and measles vaccines.
    Melnick JL
    Dev Biol Stand; 1996; 87():155-60. PubMed ID: 8854012
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Studies on the loss of infectivity of live type 3 poliovaccine on storage.
    Pipkin PA; Minor PD
    Biologicals; 1998 Mar; 26(1):17-23. PubMed ID: 9637745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stabilisation of poliovirus with pirodavir.
    Rombaut B; Andries K; Boeyé A
    Dev Biol Stand; 1996; 87():173-80. PubMed ID: 8854015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Are childhood immunization programmes in Australia at risk? Investigation of the cold chain in the Northern Territory.
    Miller NC; Harris MF
    Bull World Health Organ; 1994; 72(3):401-8. PubMed ID: 8062398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Collaborative study for the establishment of the Ph. Eur. BRP for oral poliomyelitis vaccine (OPV) Batch 3 for use in the potency assay.
    Buchheit KH; Daas A; Stalder J
    Pharmeuropa Spec Issue Biol; 2002 Jun; 2002(1):67-91. PubMed ID: 12448032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. WHO recommendation on potential use of new poliomyelitis vaccines.
    Ghendon Y
    Dev Biol Stand; 1993; 78():133-7; discussion 138-9. PubMed ID: 8388823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral iodine supplementation does not reduce neutralizing antibody responses to oral poliovirus vaccine.
    Taffs RE; Enterline JC; Rusmil K; Muhilal ; Suwardi SS; Rustama D; Djatnika ; Cobra C; Semba RD; Cohen N; Asher DM
    Bull World Health Organ; 1999; 77(6):484-91. PubMed ID: 10427933
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Capsid and RNA stabilisation of the oral polio vaccine.
    Verheyden B; Andries K; Rombaut B
    Vaccine; 2001 Feb; 19(15-16):1899-905. PubMed ID: 11228359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stability of yellow fever vaccine.
    Monath TP
    Dev Biol Stand; 1996; 87():219-25. PubMed ID: 8854020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stability testing requirements for vaccines--draft guidelines of the International Conference on Harmonization.
    Haase M
    Dev Biol Stand; 1996; 87():309-18. PubMed ID: 8854031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ensuring preparedness for potential poliomyelitis outbreaks: Recommendations for the US poliovirus vaccine stockpile from the National Vaccine Advisory Committee (NVAC) and the Advisory Committee on Immunization Practices (ACIP).
    Alexander L; Birkhead G; Guerra F; Helms C; Hinman A; Katz S; LeBaron CW; Modlin J; Murphy TV; ;
    Arch Pediatr Adolesc Med; 2004 Dec; 158(12):1106-12. PubMed ID: 15583093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A heat-stable oral polio vaccine -- waiting for a decision. CVI goal: vaccines that withstand heat.
    CVI Forum; 1995 Oct; (10):19-20. PubMed ID: 12290722
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A developing country perspective on vaccine-associated paralytic poliomyelitis.
    John TJ
    Bull World Health Organ; 2004 Jan; 82(1):53-7; discussion 57-8. PubMed ID: 15106301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a more thermostable poliovirus vaccine.
    Milstien JB; Lemon SM; Wright PF
    J Infect Dis; 1997 Feb; 175 Suppl 1():S247-53. PubMed ID: 9203724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stabilising oral poliovaccine at high ambient temperatures.
    Newman JF; Tirrell S; Ullman C; Piatti PG; Brown F
    Dev Biol Stand; 1996; 87():103-11. PubMed ID: 8854007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Preparation and evaluation of an internal reference of oral polio vaccine].
    Husson-van Vliet J; Lemoine PE
    Arch Belg; 1989; 47(7-8):261-70. PubMed ID: 2486229
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concomitant use of the oral pentavalent human-bovine reassortant rotavirus vaccine and oral poliovirus vaccine.
    Ciarlet M; Sani-Grosso R; Yuan G; Liu GF; Heaton PM; Gottesdiener KM; Arredondo JL; Schödel F
    Pediatr Infect Dis J; 2008 Oct; 27(10):874-80. PubMed ID: 18756184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence for a causal association between oral polio vaccine and transverse myelitis: A case history and review of the Literature.
    Kelly H
    J Paediatr Child Health; 2006 Apr; 42(4):155-9. PubMed ID: 16630313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.